BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-485@pharmaconomics
DTSTAMP:20260707T014501Z
DTSTART;VALUE=DATE:20240831
DTEND;VALUE=DATE:20240901
SUMMARY:BIIB Phase 2 — EMPAVELI
DESCRIPTION:Phase 2 trial results for EMPAVELI in C3 glomerulopathy (C3G) or primary IC-MPGN are due Aug 31\, 2024. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/875045/000119312526134889/d14986dex992.htm\n\nTrack it: https://pharmaconomics.com/e/485
URL:https://pharmaconomics.com/e/485
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BIIB catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR